Modest improvement in survival of patients with refractory anemia with excess blasts in the hypomethylating agents era in the United States.
about
A call for action: Increasing enrollment of untreated patients with higher-risk myelodysplastic syndromes in first-line clinical trials.Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs de novo myelodysplastic syndromes: a report on behalf of the MDS Clinical Research Consortium.Hypomethylating agents in myelodysplastic syndromes and population-level outcomes: a changing landscape or a small dent?More is less, less is more, or does it really matter? The curious case of impact of azacitidine administration schedules on outcomes in patients with myelodysplastic syndromes.Counseling patients with higher-risk MDS regarding survival with azacitidine therapy: are we using realistic estimates?
P2860
Modest improvement in survival of patients with refractory anemia with excess blasts in the hypomethylating agents era in the United States.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Modest improvement in survival ...... ents era in the United States.
@en
type
label
Modest improvement in survival ...... ents era in the United States.
@en
prefLabel
Modest improvement in survival ...... ents era in the United States.
@en
P2093
P2860
P1433
P1476
Modest improvement in survival ...... ents era in the United States.
@en
P2093
Amer M Zeidan
Amy J Davidoff
Cary P Gross
Gregory A Abel
Scott F Huntington
Steven D Gore
Xiaomei Ma
P2860
P304
P356
10.1080/10428194.2016.1214954
P577
2016-08-25T00:00:00Z